LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Inicio・Lista de Acciones・Kura Oncology Inc

Kura Oncology Inc

Cerrado

SectorSanidad

9.41 0.86

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

9.34

Máximo

9.44

Métricas clave
By Trading Economics
Ingresos	-6.9M -81M
Ventas	-3.4M 17M
Margen de beneficios	-467.23
Empleados	260
EBITDA	-12M -86M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+198.62% upside

Dividendos
By Dow Jones
Próximas Ganancias	12 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	66M 821M
Apertura anterior	8.55
Cierre anterior	9.41

Noticias sobre sentimiento de mercado

By Acuity

50%

192 / 347 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

5.575 / 6.6 Soporte y Resistencia

Kura Oncology Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

8 may 2026, 23:55 UTC

Ganancias

Review & Preview: Still Going Strong -- Barrons.com

8 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

8 may 2026, 20:49 UTC

Ganancias

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 may 2026, 20:25 UTC

Ganancias

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 may 2026, 19:43 UTC

Ganancias

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 may 2026, 19:43 UTC

Ganancias

Cencosud 1Q Net $115M

8 may 2026, 19:20 UTC

Charlas de Mercado

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 may 2026, 19:18 UTC

Ganancias

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 may 2026, 19:16 UTC

Ganancias

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 may 2026, 19:08 UTC

Ganancias

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 may 2026, 19:05 UTC

Ganancias

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 may 2026, 19:02 UTC

Charlas de Mercado

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 may 2026, 18:51 UTC

Ganancias

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 may 2026, 18:49 UTC

Ganancias

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 may 2026, 18:41 UTC

Ganancias

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 may 2026, 17:38 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 may 2026, 17:14 UTC

Ganancias

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 may 2026, 17:04 UTC

Charlas de Mercado

Zcash Caps Off Parabolic Week -- Market Talk

8 may 2026, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

8 may 2026, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

8 may 2026, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

8 may 2026, 15:39 UTC

Charlas de Mercado

Gold Seen Transitioning Away From 'Corrective Phase' -- Market Talk

8 may 2026, 15:39 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 may 2026, 15:39 UTC

Charlas de Mercado

Canada's Job Market Sees Worst Start in Years -- Market Talk

8 may 2026, 15:36 UTC

Charlas de Mercado

A Jump in Canada's Jobless Rate May Turn Out to Be a Blip -- Market Talk

8 may 2026, 15:20 UTC

Charlas de Mercado

'Altcoin Season' Indicator on the Rise -- Market Talk

8 may 2026, 15:20 UTC

Charlas de Mercado

Ganancias

Enbridge Gas Pipelines, Distribution Units Drive 1Q Beat -- Market Talk

8 may 2026, 15:05 UTC

Charlas de Mercado

Bitcoin Slips Back Below the $80k Mark -- Market Talk

8 may 2026, 14:42 UTC

Charlas de Mercado

Tough Times for Canadian Teenagers Looking for Work -- Market Talk

8 may 2026, 14:39 UTC

Charlas de Mercado

Canadian Labor Market Suggests Persistent Higher Inflation Unlikely -- Market Talk

Comparación entre iguales

Cambio de precio

Kura Oncology Inc previsión

Precio Objetivo

By TipRanks

198.62% repunte

Estimación a 12 Meses

Media 28.13 USD 198.62%

Máximo 40 USD

Mínimo 15 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Kura Oncology Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

Comprar

Mantener

Vender

De acuerdo con 10 analistas que ofrecen calificaciones bursátiles a para Kura Oncology Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

5.575 / 6.6Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimiento

By Acuity

192 / 347 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.